Excellent article for practical tips by Ivy Riano, M.D. and Dr Ibrahim Azam- great read for fellows!! Dartmouth Cancer Center Wayne State University Mayo Clinic Hematology-Oncology Fellowship Hem-Onc Fellows Network HemOnc Today OncoDaily Society of Hematologic Oncology (SOHO) Noha N. Soror, MD, MSc. 𓂀 chadi nabhan MD, MBA, FACP Hematology & Oncology Women Physicians Group—HOWPG IMG Oncologists

Jasmine Kamboj, MD, FASCO chadi nabhan MD, MBA, FACP Ivy Riano, M.D. Dartmouth Cancer Center Wayne State University Mayo Clinic Hematology-Oncology Fellowship Hem-Onc Fellows Network HemOnc Today OncoDaily Society of Hematologic Oncology (SOHO) Noha N. Soror, MD, MSc. 𓂀 Hematology & Oncology Women Physicians Group—HOWPG IMG Oncologists “…input from community oncologists to help shape the curriculum is crucial. As most trainees won’t stay in academia, they deserve an education that prepares them for the operational, emotional, and practical realities of life in the field.” 👍🥰

#radonc #lcsm NRG-CC003 trial: Hippocampal avoidance (HA) during prophylactic cranial irradiation (#PCI) in small cell lung cancer (#SCLC) didn't meet primary endpoint for 6-month Hopkins Verbal Learning Test–Revised (HVLT-R) Delayed Recall preservation (30.0% vs 25.5%

Spicy take: medical credentialing/priviliging in 2025 wastes $ billions and doesn't protect anyone. We should have single, nationwide priviliging for every provider (and national med licenses while we're at it) run by some neutral consortium that every hospital has to follow.

Highly recommend reading this great article by Drs. Ivy Riano, M.D. and Ibrahim Azar, MD. Lots of great tips and advice for hematology and oncology fellows ✨️

Nice work! There is no rationale reason not to screen HER2+ patients for brain metastases. 1) smaller lesions, SRS easier and less radiation necrosis, less morbidity 2) we have two drugs that improve OS in Brain Mets We don’t need RCTs here…

Phil and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s Knight Cancer Institute to transform the future of cancer care and set a new standard globally. Thank you to Phil and Penny Knight for their incredible generosity.

Unpopular opinion Medical education in our country is broken. It's creates great drs and is too long, too expensive and too outdated. Nurse education was accelerated very quickly to solve an issue. Why the f can't we do this with Dr education. They do it in other

Zongertinib has been added to the NCCN guidelines. 7 days from approval (Aug 8) to addition (Aug 15) is great real-time speed underlining enthusiasm for approval. NCCN encompasses "...oncogenic and likely oncogenic mutations" with a broader inclusion than TKD-restricted FDA

As men approach 80 with localized prostate cancer, the risk that local treatment (particularly surgery, but also RT) will significantly decrease quality of life is significantly higher then the likelihood that local therapy will extend their length of life. This has come up a

It was an absolute pleasure to be part of this high-yield board review course by #MSHO presenting everything one needs to know about Melanoma!

Hot off the presses, probably my favorite interventional paper of 2025 (doesn't hurt that I look up to several of the authors as mentors or role models). 💉RAS vaccination is starting to look less like fantasy, more like reality. 🆕 Nature Medicine | Wainberg et al 🎯

Survival after incidental vs symptomatic FL: - 908 pts, 29% incidental - incidental: more early stage & normal LDH - no diff in EFS, lymphoma-specific survival, or OS between groups We can answer the "what if this was picked up earlier" question! #lymsm nature.com/articles/s4140…

Academic medicine is bleeding talent. The best experts are counting to retire or switch careers at an alarming rate. It’s folly to think that you can replace top talent easily — you will need 10 people to provide the level of productivity of one top talent. The effects may

☢️ Finally published the High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for LS-SCLC. ✅OS 43.5 versus 22.5 mo, (HR 0.68, 95% CI 0.48–0.98, p = 0.037) No more acute or late onset toxicity. ✅ Would you now consider 60 Gy bid the new standard of care? #LCSM

Thrilled to share our extensive work on LCNEC in collaboration with many centers and Caris Life Sciences now out in Nature Communications labour of love for 2+ years led by tireless efforts from Amin Nassar, MD and several others! nature.com/articles/s4146… Anne Chiang Chul Kim OU College of Medicine

Kudos to Rafeh Naqash, MD Amin Nassar, MD Anne Chiang Chul Kim for leading this collaborative effort! Finally shedding some light on LCNEC: - Comparable survival with chemo, chemo-IO, or IO - 2 molecular subtypes: NSCLC-like (KRAS, STK11, KEAP1) vs SCLC-like (TP53, RB1) -

Interesting data showing early-onset PDAC may be enriched for druggable alterations compared to average-onset. 🧬 In 224 PDAC pts: 23.2% (52/224) were KRAS-wt. Actionable TIER I–III alterations:  • KRAS-wt: 23.1% (12/52)  • KRAS-mut: 11.6% (20/172)  (P=0.04) Gene fusions:

Small rectal NETs are common and incidence is increasing. How should we follow patients? This >1000 pt study suggests that recurrences rarely occur following resection of ≤0.7 cm G1 NETs and surveillance may not be needed. Highly relevant paper. onlinelibrary.wiley.com/doi/10.1111/de…

Mayo Clinic retrospective analysis: Induction chemo+ IO → cCRT → +/- maintenance ICI appears feasible in stage III NSCLC patients not suitable for upfront cCRT (n:29) ORR➡️ 93% (induction phase) mPFS➡️18 mo mOS➡️24 mo ❗️Adverse events: pneumonitis 37.9% (≥grade 3: 18%),